Navigation Links
Alzheimer's Treatment Trials May Have Special Challenges
Date:7/28/2008

Studies may need larger pools of participants to accurately assess if drugs are effective

MONDAY, July 28 (HealthDay News) -- It may be harder to prove the effectiveness of new Alzheimer's disease therapies, because researchers have been having a hard time finding measurable decline in memory and thinking processes in the placebo groups the drugs are being tested against, according to two new reports.

Several discoveries may explain this, according to the reports, which are expected to be presented Monday in Chicago at the Alzheimer's Association's International Conference on Alzheimer's Disease.

In the first study, researchers looked at 87 randomized, double-blind, placebo-controlled Alzheimer clinical trials conducted between 1991 and 2005. Their analysis help set conditions that may be optimal in these types of trials.

"Based on our analysis, the most reliable approach to maximize the likelihood for demonstrating efficacy is to have a placebo group size greater than 200 and to use (cognitive testing methods) at least four times and in English," researcher Dr. Lon S. Schneider, professor of psychiatry and neurology at the University of Southern California Keck School of Medicine, said in a news release issued from the conference.

The second study, which looked at trials of the drug donepezil during the 1990s, showed that the length of the placebo study may be of increasing importance. Placebo groups experienced slower declines in cognitive functions in trials done later in the decade, but this was mitigated when the trial period was longer.

"Our results indicate that patients with Alzheimer's entering the later clinical trials appear to be experiencing a slower rate of decline in memory and thinking processes," researcher Roy Jones, director of The Research Institute for the Care of Older People, in Bath, England, said in the same news release. "These observations are potentially important for the future design of clinical trials in people with Alzheimer's. For example, it may be necessary to conduct longer duration research studies -- more than 24 weeks -- to ensure any effects of treatment can be fully evaluated."

More information

The Alzheimer's Association has more about Alzheimer's disease.



-- Kevin McKeever



SOURCE: Alzheimer's Association, news release, July 28, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Alzheimers Research Target May Be a Dead End
2. Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting
3. Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi
4. Researchers disprove long-standing belief about HIV treatment
5. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
6. Clinical Trial Concluded For New Wrinkle Treatment
7. Has cancer spread? Research identifies best way to find answers so treatment can begin
8. Minimally Invasive Treatment Improves Male Fertility
9. Minimally invasive treatment improves male fertility
10. Clinical Trial for the Treatment of Inflammatory Bowel Disease Begins at Tel Aviv Sourasky Medical Center
11. Promising results in deep brain stimulation for patients with treatment-resistant depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: